Alumis Inc. (ALMS) fair value analysis
Nasdaq · Updated 2026-10-19
ALMS price how computed
Valuation status
No fair-value estimate yetALMS has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ALMS yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $6.12
- Sector
- Healthcare
- 12-month range
- $4.51–$30.30
- Market cap
- $792M
- From 52-week high
- -79.8%
- Shares outstanding
- 129M
- Rank in Healthcare by quality score
- #175 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for severe inflammatory and autoimmune diseases. The company is based in the United States and operates as a publicly traded entity on the Nasdaq stock exchange.
ALMS currently ranks #175 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $792M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $7.4M
- Net margin
- -5933.5%
- EPS (TTM)
- $-2.83
- Gross margin
- 100.0%
- Debt / equity
- 0.08
- Shares outstanding
- 129M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 30 · oversold
- 50-day average
- $13.57
- 200-day average
- $21.91
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-12
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▼ miss (-11.4%)
2026-03 ▲ beat (+3.9%)
2025-12 ▲ beat (+74.5%)
2025-09 ▼ miss (-15.2%)
2025-06 ▼ miss (-5.8%)
2025-03 ▼ miss (-28.2%)
2024-12 ▼ miss (-31.8%)
2024-09 ▼ miss (-0.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 1 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $31.1
- Target vs last price
- +408.2%
What our data shows for ALMS
- Shares are trading in the lower third of their 12-month price range of $4.51–$30.30.
- The 14-day relative strength index sits at an oversold 30.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ALMS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ALMS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ALMS stock undervalued?
TickrTrends has no fair-value estimate for ALMS yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ALMS's TickrTrends verdict?
ALMS is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ALMS compare to other Healthcare stocks?
ALMS ranks #175 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ALMS overbought or oversold?
ALMS's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does ALMS report earnings next?
ALMS's next earnings report is scheduled for 2026-11-12, per the published earnings calendar.
Does ALMS usually beat earnings estimates?
Over its last 8 reported quarters ALMS beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ALMS?
Of 10 analysts covering ALMS, 9 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $31.1 (+408.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.